PG

Business Context and Reporting Period

This Form 10-Q covers The Procter & Gamble Company for the quarterly period ended March 31, 2002, and the nine-month period ended on the same date. The company operates globally across five primary segments: Baby, Feminine & Family Care; Fabric & Home Care; Beauty Care; Health Care; and Food & Beverage. A significant event during this period was the acquisition of the Clairol business from Bristol-Myers Squibb for approximately $5 billion in cash, completed in November 2001.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 4% for the quarter and 3% for the nine-month period compared to the prior year. Unit volume grew 10% in the quarter, driven by double-digit growth in Health and Beauty Care.
• Profitability: Net earnings rose 16% for the quarter ($1.04 billion vs. $893 million) and 6% for the nine-month period ($3.44 billion vs. $3.24 billion). Core net earnings (excluding restructuring and accounting changes) grew 7% to $2.83 per share for the nine-month period.
• Margin Expansion: Operating margin improved to 16.7% from 13.7% in the prior year quarter, driven by gross margin improvements (48.8% vs. 45.6%) and lower commodity costs.
• Acquisition Impact: The Clairol acquisition contributed significantly to Beauty Care volume (28% growth) and sales, though it negatively impacted cash flow due to the $5 billion purchase price.
• Restructuring Charges: The quarter included a $147 million after-tax restructuring charge ($191 million pre-tax), compared to $113 million after-tax in the prior year quarter. The nine-month period included $531 million in after-tax restructuring charges.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted strong volume growth and disciplined cost management. Capital expenditures were down significantly ($1.2 billion for nine months vs. $1.9 billion prior year), achieving the 6% of sales target ahead of schedule.
• Restructuring Program: The company continues a multi-year restructuring program initiated in 1999. Charges in the quarter included $51 million for employee separations (approx. 1,000 people) and $83 million for asset-related charges.
• Accounting Changes: The company adopted SFAS No. 142, discontinuing the amortization of goodwill and indefinite-lived intangible assets effective July 1, 2001. This resulted in a $56 million after-tax benefit in the prior year quarter that is not present in the current period.
• Risks and Contingencies:
  • Foreign Exchange: Had a negative 3% impact on net sales for the quarter.
  • Integration: Costs associated with integrating Clairol increased marketing and administrative expenses.
  • Valuation Adjustments: The allocation of the Clairol purchase price is subject to revision based on final fair value appraisals, expected to be finalized in the fourth quarter.

Investor Verification Checklist

• Clairol Integration: Verify the final purchase price allocation and the timeline for realizing anticipated synergies.
• Restructuring Costs: Monitor the remaining cash reserves for restructuring ($399 million as of March 31, 2002) and future charges related to the multi-year program.
• Debt Levels: Assess the impact of the $5 billion Clairol acquisition on long-term debt levels and interest expense coverage.
• Core Earnings: Distinguish between reported earnings and core earnings to understand the impact of one-time restructuring charges and accounting changes.
• Volume vs. Pricing: Confirm the sustainability of the 10% unit volume growth given the negative 3% impact from pricing and mix adjustments.